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ARTICLE
Comprehensive, Multimodal Characterization
of an Imiquimod-Induced Human Skin Inflammation
Model for Drug Development
Tessa van der Kolk1, Salma Assil1, Rianne Rijneveld1, Erica S. Klaassen1, Gary Feiss2, Edwin Florencia3, Errol P. Prens3,
Jacobus Burggraaf1, Matthijs Moerland1, Robert Rissmann1 and Martijn B.A. van Doorn3,∗
Imiquimod (IMQ) is often used as a topical challenge agent to provoke local skin inflammation. The objec-
tive of this study was to develop and refine a rapid, temporary, and reversible human skin inflammation
model with IMQ for application in clinical drug development. A randomized, vehicle-controlled, open-label,
dose-ranging study was conducted in 16 healthy male subjects. IMQ (5 mg) was applied once daily for
72 hours under occlusion to intact skin (n = 8) or tape stripped (TS) skin (n = 8). Although IMQ alone
induced limited effects, TS+IMQ treatment showed larger responses in several domains, including ery-
thema and perfusion (P< 0.0001), mRNA expression of inflammatory markers (P< 0.01), and inflammatory
cell influx compared with vehicle. In conclusion, a rapid, human IMQ skin inflammation challenge model
was successfully developed with a clear benefit of TS prior to IMQ application. Future interaction studies
will enable proof-of-pharmacology of novel compounds targeting the innate immune system.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Murine skin inflammation models with imiquimod are
widely implemented to study skin inflammation. No healthy
volunteer models for the application in drug development
programs were explored before.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ What is the most suitable skin inflammation model
with imiquimod in healthy volunteers for drug development
programs?
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ Imiquimod application with tape stripping prior to the
first dose administration is a suitable model to quickly
induce temporary skin inflammation in healthy volunteers.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔ Future interaction studies with the model will enable
proof-of-pharmacology of novel compounds targeting the
innate immune system in healthy volunteers.
Skin inflammation is a physiological immune response to
various stimuli including skin trauma, physical challenge,
and exposure to xenobiotics, microbes, and parasites. Dys-
regulation of this immune response is involved in chronic
inflammatory skin diseases, e.g., psoriasis vulgaris, acne vul-
garis, and atopic dermatitis.1,2 Although much mechanistic
insight has been gained, including involvement of the innate
immune system via Toll-like receptors (TLRs) and the adap-
tive immune system, the pathophysiology of skin inflamma-
tion is complex and remains to be elucidated further.3
Different models that mirror aspects of chronic inflamma-
tion have been developed to study skin inflammation. For
instance, rapid, acute skin inflammation can be induced by
topical, cutaneous application of imiquimod cream (IMQ;
Aldara). IMQ application leads to agonistic activation of
TLR7- and TLR8-mediated MyD88 signaling, activation of
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nuclear factor kappa B (NF-қB), and the induction and
release of proinflammatory cytokines, type-1 interferons,
chemokines, and other mediators. Ultimately, this leads to
an innate and Th1- and Th17-weighted cellular immune acti-
vation and enhancement of proinflammatory effects.4
Although the use of IMQ appears to be safe and reason-
ably tolerated, disease exacerbation can occur in psoriasis
patients and even the development of psoriasis in individuals
without a prior history of the disease is reported.5–10 Based
on the initial findings, the first IMQ-induced skin inflam-
mation mouse model was successfully developed.11 This
model has become widely accepted for preclinical studies of
psoriasis because of its straightforward approach, inexpen-
siveness, and the fast acute inflammatory response.11,12 Nev-
ertheless, themurinemodel has some crucial disadvantages,
the major ones being immediate systemic effects and the
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limited extrapolation of murine findings to humans due to dif-
ferences in the immunology and TLRs.12,13
Therefore, several skin inflammationmodels with IMQ have
been evaluated in humans. A short, 7-day model in psoriasis
patients using IMQ next to tape stripping (TS) showed that
psoriasis-like skin inflammation occurred but typical psoria-
sis did not develop.5 Contact dermatitis driven by plasma-
cytoid dendritic cells (pDC) was observed in an extended
model of 4 weeks, both in healthy volunteers and in patients
with inflammatory skin diseases. Only limited aspects of
the molecular signature of psoriasis were observed.14 Other
studies in healthy volunteers characterized the model by
either solely focusing on biopsy biomarkers or only systemic
effects after high topical doses of IMQ.15,16 Acute and rapid
IMQ-induced inflammation models in healthy volunteers with
detailed characterization have not yet been reported. A well-
characterized, comprehensive human model to study skin
inflammation would open opportunities for understanding
the pathogenesis of several skin diseases and for the pro-
filing of novel drugs in development.
With this study we aimed to develop a skin inflammation
challenge model with i) topical IMQ application for 24, 48,
and 72 hours on a fully competent skin barrier, and ii) topical
IMQ application for 24, 48, and 72 hours on TS-perturbed
skin barrier to enhance drug delivery. Cetomacrogol cream,
an indifferent neutral emollient, was used as the control. Skin
inflammation was assessed by measurement of erythema,
perfusion, and using biopsy material (mRNA expression, his-
tology, immunohistochemistry). In the future, these models
may be used in drug development programs for proof-of-
pharmacology, drug profiling, or interaction studies of novel
compounds targeting the innate immune system and trans-
lational research of inflammatory skin diseases.
METHODS
The protocol of this randomized, open-label, vehicle-contr-
olled, parallel-cohort, dose-ranging study was approved by
the independent Medical Ethics Committee “Medisch Ethis-
che Toetsingscommissie van de Stichting Beoordeling Ethiek
BiomedischOnderzoek” (Assen, TheNetherlands). The study
was conducted according to the Dutch Act on Medical
Research involving Human Subjects (WMO). Subjects were
recruited throughout the Netherlands via advertisement cam-
paigns on the Internet and in the newspaper. All subjects
gave informed consent prior to any study procedure. The
study was conducted from May 2016 to June 2016 at the
Centre for Human Drug Research, Leiden, The Netherlands.
Study population
Sixteen16 healthy male Caucasian (Fitzpatrick skin type I–II)
volunteers, aged 18–45 years, were included in the study.
Health status was verified with a medical history, physical
examination, laboratory tests, and 12-lead electrocardiodia-
grams (ECG). Subjects with amedical history or family history
of psoriasis or any disease associated with immune system
impairment were excluded from the study. Previous use of
imiquimod, resiquimod, or gardiquimod was not allowed.
IMQ treatment
Prior to the first dose administration, four treatment areas
(squares) were identified on the upper back and marked with
a dermatological marker. During the treatment period a stan-
dard daily dosage containing 5 mg IMQ (100 mg Aldara)
was applied under occlusion by a 12-mm Finn chamber
(Smart Practice, Phoenix, AZ), meaning the Finn chamber
was replaced with a new dose after 24 hours. Treatment area
1 was treated 1 day (5 mg IMQ, 24 hours), treatment area
2 was treated 2 days (cumulative 10 mg IMQ, 48 hours),
and treatment area 3 was treated for 3 days (cumulative
15 mg IMQ, 72 hours). Treatment area 4 was treated with
100 mg cetomacrogol (indifferent) cream for 72 hours (neg-
ative control) (Figure 1a). The sample size and dose were
selected based on a previous study with imiquimod in healthy
volunteers. Given the exploratory character of the study, no
formal power calculation was performed. Subjects were ran-
domized 1:1 to receive these treatments either over a fully
competent skin barrier or over a disrupted skin barrier by TS
of the skin. Tape stripping enhances drug delivery over the
skin barrier. It is known from the literature that only a lim-
ited amount of drug can be delivered over a fully compe-
tent barrier. Given the short treatment duration in this study
it was decided to tape strip one group before application to
ensure drug delivery. The TS procedure was performed as
follows: tape (D-Squame, CuDerm, Dallas, TX) was applied
to the marked treatment area and a roller was used to press
the tape to the skin to avoid furrows and wrinkles by a single
operator. After this the tapewas removed at a constant veloc-
ity. The procedure was repeated for at least 15 times until the
transepidermal water loss (TEWL) by Aquaflux (BioX, Lon-
don, UK) was between 20–25 g/m2h (partial removal of the
stratum corneum). Safety and tolerability were monitored by
recording adverse events.
Clinical scores
Clinical assessments were performed daily of treatment area
3 and 4, and included visual erythema grading (Clinician
Erythema Assessment (CEA) scale, 0 represents absence
of erythema, 4 very severe), colorimetry (a* value (DSM II
ColorMeter, Cortex Technology, Hadslund, Denmark) with a
total of three repeats on each treatment area, 2D photogra-
phy erythema index analysis, and perfusion by laser speckle
contrast imaging (LSCI; PeriCam PSI System, Perimed
Jäfälla, Sweden).
Transdermal analysis patch (TAP)
Skin surface biomarkers were collected predose and after 1,
2, and 3 days of treatment by with TAP (FibroTx, Estonia).
TAP consists of a multiplex capture-antibody microarray that
is supported by a dermal adhesive bandage for fixture to skin
and can measure up to six markers per TAP. IFN-β, IFN-γ ,
Il-8, IL-6, HBD-2, IL-1b were chosen and captured from skin
and were qualitatively and quantitatively analyzed by spot-
ELISA (enzyme-linked immunosorbent assay).
Skin punch biopsies
Three millimeter skin biopsies were collected predose (of
tape stripped skin in the TS cohort), 24 hours after end-of-
treatment of each treatment area, and from a distant site with
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Figure 1 (a) Treatment schedule of the study. Treatment areas 1 and 2 served as biopsy sites for biopsies after 1 (24 hours) and 2 (48
hours) days of treatment. Treatment sites 3 and 4 served as sites for all erythema and perfusion measurements and biopsies after the
longest treatment duration (3 days, 72 hours, 5 mg imiquimod (IMQ) application at 0 hour, 24 hours, and 48 hours). In eight subjects the
local treatment area was tape stripped before IMQ application. All treatments were applied under occlusion by a 12-mm Finn chamber.
(b) Clinical impression of site 3, tape stripping (TS)+IMQ 72 hours. An increase of erythema and perfusion is observed.
a total of six biopsies per subject. After harvest, the biop-
sies were placed in RNAlater medium and stored at 4°C.
The biopsy samples were analyzed at the Immunology Lab-
oratory at Erasmus MC, Rotterdam, The Netherlands. RNA
extraction and real-time quantitative polymerase chain reac-
tion (PCR) analysis was performed for the following biomark-
ers: IP10/CXCL10, IFN-β, IFN-γ , TNF-α, IL-1β, IL-6, HBD-2,
MX1, MXA, and ICAM-1, which were chosen based on the
murine model. Additionally, a histopathological score was
obtained of hematoxylin and eosin (H&E)-stained tissue by
two blinded persons for the following characteristics of psori-
asis and dermatitis: general infiltration (all types of inflamma-
tory cells present), parakeratosis, acanthosis, papillomatosis,
and spongiosis. The histopathological score for each charac-
teristic was graded based on the fold increase or decrease
compared with a reference biopsy of a healthy subject not
related to the clinical trial (1; equal to the reference biopsy, 2;
twofold increase compared with the reference biopsy, etc.).
Furthermore, immunohistochemical staining was performed
to obtain scoring of markers CD11c, CD14, CD1a, CD4, CD8,
and HLA-DR. This was also performed by two blinded per-
sons and graded the same way as for the histopathological
characteristics.
Statistics
All calculations were performed using SAS for windows v.
9.4 (SAS Institute, Cary, NC). Treatment effects were ana-
lyzed with a mixed model analysis of variance with fixed
factors treatment, cohort, time, treatment by cohort, treat-
ment by time, cohort by time and treatment by cohort
by time, random factors subject, subject by treatment and
subject by time, and the baseline measurement as covari-
ate. To determine the differences among the treatments,
contrasts on all measurements were calculated. Analysis
results per variable were generated with estimates of the
difference of the different contrasts and a back-transformed
estimate of the difference in percentage for log-transformed
parameters, 95% confidence intervals (CI) (in percentage for
log-transformed parameters), and Least Square Means (geo-
metric means for log-transformed parameters), and the P-
value of the contrasts.
RESULTS
In total, 35 subjects were screened, of whom 26 subjects
were eligible for participation in the study. All of the 16
included subjects completed the study and the treatments of
IMQ or TS+IMQ were administered as depicted in Figure 1a.
The study participants were all Caucasian and had a mean
age of 22.3 (18–33) years. The treatments were in general well
tolerated. The most frequent occurring treatment-emergent
adverse event was application site pruritus, observed in 25%
of the participants of both IMQ treatments. No increase in
IFN-α or IFN-ɣ was detected in the systemic circulation.
IMQ application induced reversible erythematous
hyperperfused skin lesions
A clear exposure-dependent increase in erythema was
observed with IMQ and TS+IMQ for all erythema measure-
ments compared with the control as determined by erythema
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Figure 2 Erythema and perfusion induced by IMQ and TS+IMQ application. Error bars are defined as LSM ±upper and lower limit.
(a) LSM change from baseline in erythema index, (b) LSM change from baseline in erythema by colorimetry, (c) LSM change from baseline
in % by laser speckle contrast imaging, (d) erythema by visual grading displayed as % presence per timepoint.
Table 1 Analysis results of erythema and perfusion measurements
IMQ vs. vehicle TS + IMQ vs. TS + vehicle
24 hours 48 hours 72 hours 24 hours 48 hours 72 hours
Erythema index 9.18 11.55 16.84 18.64 29.76 36.53
(–1.37, 19.73) (1.00, 22.10) (6.29, 27.38) (7.89, 29.38) (19.01, 40.50) (25.78, 47.28)
P = 0.09 P = 0.03 P = 0.003 P = 0.001 P = <.0001 P = <.0001
Colorimetry 1.16 2.16 3.66 3.22 5.13 5.64
(–0.34, 2.66) (0.66, 3.65) (2.16, 5.16) (1.72, 4.73) (3.6, 6.64) (4.13, 7.15)
P = 0.12 P = 0.006 P = <.0001 P = 0.0001 P = <.0001 P = <.0001
Basal Flow (% change) –3.1% 1.2% 6.6% 21.0% 44.0% 38.8%
(–13.5%, 8.5%) (–9.6%, 13.4%) (–4.9%, 19.4%) (7.0%, 36.9%) (28.5%, 61.4%) (23.8%, 55.5%)
P = 0.57 P = 0.83 P = 0.26 P = 0.003 P = < 0.0001 P = < 0.0001
The differences between imiquimod (IMQ) vs. vehicle and tape stripping (TS)+IMQ vs. TS+vehicle are shown. Data are presented as mean, 95% confidence
interval, and P-value.
index (EI) photo analysis, erythema by colorimetry, and ery-
thema by visual grading (Figure 1b, Figure 2). Upon 48
hours IMQ treatment, the difference with vehicle was statis-
tically significant (P < 0.05) (EI; 11.55, 95% CI 1.00–22.10,
P = 0.03; colorimetry; 2.16, 95% CI 0.66 – 3.65, P = 0.006,
Table 1). TS+IMQ resulted in more significant contrasts (P <
0.01) comparedwith vehicle and thesewere already achieved
after 24 hours (EI; 18.64, 95% CI 7.89–29.38, P = 0.001,
colorimetry; 3.22, 95% CI 1.72 – 4.73, P = 0.0001, Table 1).
An exposure-dependent increase in perfusion that plateaued
after 48 hours was only observed with TS+IMQ (Figure 2c).
Concordant with the erythema, this increase was already sta-
tistically significant 24 hours after application (21%, 95%
CI 7.0–36.9%, P = 0.003, Table 1). TS itself did not induce
significant changes in erythema and perfusion (Supporting
Figure S1). The skin clinically recovered after end of treat-
ment (not shown).
IMQ-induced activation of innate immune system
Expression of CXCL10, hBD-2, ICAM-1, IFN-β, IFN-γ ,
IL-1β, IL-6, MX-1, MX-A, and TNF-α in punch biopsies was
investigated by real-time quantitative (q)PCR analysis, and
normalized for the housekeeping gene ABL. As shown in
Figure 3, CXCL10, MX-A, ICAM-1, and hBD-2 showed a
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Figure 3 mRNA expression in skin over time in IMQ and TS+IMQ treated skin of CXCL10, HBD-2, MXA, ICAM1, TNF-α and IL-1β.
Statistical significance is indicated as follows: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
statistically significant increase after 48 hours and 72 hours
in the TS+IMQ treatment group compared with the untreated
area (P < 0.01). This was only observed for hBD-2 in the IMQ
treatment group vs. untreated. In addition, an increased
expression of both TNF-α and IL-1β was observed with 48
hours and 72 hours treatment, compared with the untreated
site; this was significant for IL-1β (P < 0.05), and only
observed for the conditions without TS (Figure 3). TAP
data were highly variable and not significantly different from
untreated skin (data not shown).
Infiltration and acanthosis induced by IMQ treatment
H&E-stained skin punch biopsies were independently ana-
lyzed by two investigators blinded to treatment. In the IMQ
treatment group, no changes compared with the reference
biopsy were observed. TS+IMQ treatment demonstrated
twofold increase in general infiltration in 31% and 44% of
the subjects after 48 hours and 72 hours, respectively, com-
pared with the reference. Acanthosis as compared with the
reference was two times more frequent in 19% of these
subjects after 48 hours (Figure 3, Figure 4). Moreover,
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Figure 4 H&E (upper row) and CD8+ staining (lower row) over time of subject 15 treated with TS+IMQ. Scale bars = 100 μm.
Figure 5 Histology and immunohistochemistry in skin punch biopsies of IMQ and TS+IMQ treated skin compared with untreated skin,
displayed in % fold increase compared with the reference biopsy. (a) general infiltration, (b) acanthosis, (c) CD4+ and CD8+ infiltration,
(d) CD11c+ and HLA-DR infiltration. Fraction of subjects is depicted.
parakeratosis, papillomatosis, and spongiosis were scored.
These parameters were not different from the reference
biopsy in either cohort. No histological skin changes were
noted in the vehicle controls.
CD4+, CD8+, CD11+, and HLA-DR+ cells infiltrated
the dermis following IMQ treatment
Immunohistochemical staining was performed to further
explore cell infiltration and showed an infiltration of
CD4+ T-cells, CD8+ T-cells, CD11+ dendritic cells, and
HLA-DR+ macrophages, mostly in the TS+IMQ treatment
group. CD8+ cells were 1.5 times more present in 56% of
the subjects in the TS+IMQ treatment group after 48 hours
and 72 hours, compared with the reference biopsy (Figure 4,
Figure 5). In 37.5% of the subjects, CD4+ cells were 1.5
times more present examined after 48 hours and 72 hours
of treatment in the TS+IMQ treatment group. Moreover,
CD11c+ infiltration was slightly apparent (two times more
present in 21.4% of the subjects after 48 hours, 12.5% of
the subjects after 72 hours in TS). HLA-DR+ cells 12.5%
of the TS subjects developed a threefold increase of HLA-
DR+ cells after 48 hours of IMQ treatment, while 18.8% was
observed after 72 hours of IMQ treatment, compared with
the reference biopsy. However, HLA-DR was already more
present at baseline in this group of subjects, compared with
the reference biopsy (Figure 5).
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Figure 6 Multimodal assessment of the model including clinical (physician scoring), biophysical (laser speckle contrast imaging), imaging
(colorimetry), molecular (mRNA expression, hBD2), and cellular (IHC, CD8+) aspects. The observed maximal effect is used for normal-
ization of the respective axes. For the IMQ alone group, only increased erythema by colorimetry is observed without a dose-dependent
relationship. In the TS+IMQ group it is clearly visible that the effects on all domains spread over the spiderplot in a dose-dependent
manner.
DISCUSSION
Comprehensive characterization of the skin
inflammation model
This is the first study that comprehensively characterized an
acute inflammatory model combining IMQ and TS in healthy
volunteers with the purpose to apply it in drug development
programs. We utilized different, complementary assessment
modalites to monitor the effects thouroughly, including clin-
ical (physician scoring), biophysical (LSCI), imaging (col-
orimetry), molecular (mRNA expression), and cellular (IHC)
aspects. The synthesis of this multimodal assessment is pre-
sented in Figure 6 and clearly shows concordant effects
on complementary modalities and a clear dose-dependency,
exposure–response relationship. While previously models
were developed in psoriasis patients or with a lengthy treat-
ment period of 28 days in healthy volunteers without TS,5,14
our study shows a rapid and reproducible way of induc-
ing short-term inflammatory skin lesions with effects on all
the different domains, as discussed in detail in the next
paragraphs.
Strong agreement of measurements assessing
the clinical phenotype
IMQ induced a dose-dependent increase in erythema in
all measurements, which occured much quicker and more
pronouced when combined with TS. Statistically significant
effects on EI, colorimetry, and LSCI were already observed
24 hours after TS+IMQ treatment, vs. 48 hours without
TS. There were no clear differences in erythema inten-
sity between 48 hours and 72 hours of treatment for the
TS+IMQ treatment, which is also seen in the murine model.11
Increased skin perfusion as a result of IMQ application was
only observed when it was combined with TS, and also no
clear differences between 48 hours and 72 hours appeared.
In a recent study where a human model with 4 weeks of IMQ
treatment was developed to study psoriasis, maximal effects
occurred at day 4 or later, but TS of the skin was not per-
formed to enhance drug delivery of IMQ.14 Importantly, in our
study we showed that within 24–48 hours of the last dose,
the skin fully recovered clinically (data not shown), which is in
agreement with previous reports.5 The similar clinical obser-
vations with different methods and reversibility of effects are
two strong points of our approach.
Fully comprehensive mechanistic insights of molecular
patterns
CXCL10, MX-A, ICAM-1, and hBD-2 were all statistically
significantly upregulated in the skin of subjects treated
with IMQ for 48 hours and 72 hours in combination with
TS and to a lesser extent in the non-TS cohort (only for
hBD-2) compared with vehicle, which is concordant with
the molecular findings of Dickson et al.15 This reflects
the intermediate phase response of IMQ (24–72 hours)
where activation of the innate as well as adaptive immune
system occurs, featuring infiltration of neutrophils, lym-
phocytes, and macrophages, as described in a recent
review of the murine translational IMQ skin inflammation
models.17 CXCL10, a chemokine that is highly expressed
when keratinocytes are activated in inflamed skin, is regu-
lated by T cells and found in psoriasis and other autoim-
mune diseases, which corresponds with the findings in our
clinically induced skin inflammation.1,15,18 Upregulation of
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MX-A, a downstream mediator of interferons, reflects the
activation of plasmacytoid dendritic cells (pDCs), which play
a major role in the pathophysiology of psoriasis.1,19,20 Fur-
thermore, this refects the antiviral response by IMQ, which
was expected since IMQ is effective against several HPV-
induced skin diseases.21,22 The mRNA expression of adhe-
sion molecule ICAM-1 was observed to be upregulated,
which corroborates previous findings showing induction by
TNF-α.23 ICAM-1 facilitates leukocyte endothelial transmi-
gration and enhancement of skin inflammation. Upon IMQ
treatment alone, no statistically significant differences in
upregulation were observed between 48 hours and 72 hours
in the biopsy markers, which confirms the better suitability
of the TS+IMQ combination for further application in drug
development.
Interestingly, in the biopsies of the non-TS cohort, we
found an upregulation of TNF- α and IL-1β compared with
the untreated site, while this was not present in the TS+IMQ
cohort. Presumably, the initial phase (within 24 hours),
where the innate immune system is activated as a conse-
quence of release of inflammatorymediators including IFN-α,
IL-1α, IL-1β, IL-6, and TNF-α and where cellular changes
such as accumulation of neutrophils and proliferation of ker-
atinocytes occur, is at a later timepoint because of less drug
delivery without TS.17 This would also explain why TNF-α and
IL-1β are not upregulated in the TS cohort after 48 hours; due
to enhanced penetration by TS of the skin, the initial upregu-
lation might already have passed. This matches with the fact
that erythema was observed in the TS cohort already after
24 hours, but not in the non-TS cohort, where it appeared
after 48 hours. Moreover, the presence of ICAM-1 in the TS
cohort confirms the presence of TNF-α in an earlier stage,
and therewith the initial phase as also seen in the murine
model, since it is a downstream marker of TNF-α.23 Vin-
ter et al. did still find TNF-α and IL-1β after 48 hours, but
tape stripped less extensively (10 times vs. ± 15 times in
our study). Hereafter, both markers also normalized while the
downstream markers increased.5
Concordant cellular observations
Histologically, a general infiltration with little acanthosis was
seen only in the TS cohort. Classical dermatitis and pso-
riasis characteristics such as spongiosis, acanthosis, and
parakeratosis were not observed. Although some of those
characteristics were reported in the literature after longer
treatment, the treatment duration in this study of maximally
72 hours is presumably too short.5,14 In psoriasis patients,
exacerbations after IMQ treatment also occur only after a
prolonged period of application (average 9 weeks).7 In addi-
tion, CD11c+, HLA-DR, CD4+, and CD8+ cells infiltrated
the dermis, more in the TS cohort than in the non-TS cohort
and with no clear difference between 48 hours and 72 hours.
CD11c+ cells reflect the inflammatory myeloid DCs. These
are highly increased in the psoriatic dermis and are known
to stimulate the production of type 1 helper (Th1) cytokines.1
Likewise, the macrophages (HLA-DR) are involved in this
process, which are mediated via the TLR-7 response.24–26
Infiltration of DCs, macrophages, and T cells indicate acti-
vation of both an innate and adaptive immune response. All
histological effects are consistent with the intermediate and
late-phase response of IMQ. The late phase is characterized
by expression of both IL-17 and IL-22 as a result of IL-23
production, and infiltration of T cells. It normally occurs after
72 hours.17 However, due to the enhanced drug delivery by
TS of the skin, this was already observed in the 48-hour
biopsies.
Translational value of the inflammation model for drug
development
Taken together, the IMQ-induced histological changes are
highly similar to those that were observed in the murine
model and have features of both psoriasis and contact der-
matitis, with activation of the innate and adaptive immune
system. Concordant with findings of others, no complete
phenotype induction such as psoriasiform histology was
observed.5,14 However, since the purpose of the study was
to develop a model for drug profiling and interaction stud-
ies, and not primarily to study disease pathophysiology, this
is not considered a limitation. A limitation of the study is
the open-label design, which could have led to an observer
bias of the clinical erythema grading. However, since clini-
cal scores are highly concordant with the objective erythema
measures, EI and colorimetry, the bias is presumably negli-
gible.
In conclusion, we succesfully translated the murine IMQ
skin inflammation model to a fully characterized safe, rapid,
and reversible human model in healthy volunteers. Clinical
and histological phenotypes were fully concordant in the
TS+IMQ cohort. Therefore, TS of the skin to enhance drug
delivery of IMQ is required to induce a quicker and stronger
inflammatory response. No significant differences in effects
of IMQ were observed between 48 hours and 72 hours of
application, suggesting that 48 hours of treatment is the
most suitable for this model. Future interaction studies with
the model in drug development programs will enable proof
of pharmacology of novel compounds targeting the innate
immune system.
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